2 withdrawn. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Withdrawn 2 |
Follow Status Epilepticus: new trials by email Literature Review of Status Epilepticus trials Research Report on Status Epilepticus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| To Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus (RSE) Ganaxolone, Placebo, Standard of care - Refractory Status Epilepticus | Phase 3 | Withdrawn | Marinus Pharmaceuticals | 2024-03-01 | 2024-05-14 | |
| Levetiracetam, Lacosamide and Ketamine as Adjunctive Treatment of Refractory Status Epilepticus levetiracetam, lacosamide, Ketamine - Epilepsy, Status Epilepticus | Phase 3 | Withdrawn | Mid-Atlantic Epilepsy and Sleep Center, LLC | 2014-02-01 | 2017-08-29 |
Epilepsy (1)
Nervous System Diseases (2) · Neurologic Manifestations (2) · Pathological Conditions, Signs and Symptoms (2) · Seizures (2) · Signs and Symptoms (2) · Brain Diseases (1) · Central Nervous System Diseases (1)
Ketamine (1) · Lacosamide (1) · Levetiracetam (1) · Phenobarbital (1) · Standard of Care (1) · ganaxolone (1)
Marinus Pharmaceuticals (1) · Mid-Atlantic Epilepsy and Sleep Center, LLC (1)
Austria (1) · Belgium (1) · Croatia (1) · Czechia (1) · Finland (1) · France (1) · Germany (1) · Hungary (1) · Israel (1) · Italy (1) · Lithuania (1) · Poland (1) · Slovakia (1) · Spain (1) · Switzerland (1)